BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 14514775)

  • 21. Immunohistochemical analysis of c-erbB-2, Bcl-2, p53, p21
    Missaoui N; Landolsi H; Mestiri S; Essakly A; Abdessayed N; Hmissa S; Mokni M; Yacoubi MT
    Pathol Res Pract; 2019 Mar; 215(3):446-452. PubMed ID: 30558966
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Mucoepidermoid carcinoma of salivary glands: the prognostic value of tumoral markers].
    Hoyek-Gebeily J; Nehmé E; Aftimos G; Sader-Ghorra C; Sargi Z; Haddad A
    Rev Stomatol Chir Maxillofac; 2007 Dec; 108(6):482-8. PubMed ID: 17761202
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Molecular markers in Paget disease of the breast.
    Fu W; Lobocki CA; Silberberg BK; Chelladurai M; Young SC
    J Surg Oncol; 2001 Jul; 77(3):171-8. PubMed ID: 11455553
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Multiple molecular marker testing (p53, C-Ki-ras, c-erbB-2) improves estimation of prognosis in potentially curative resected non-small cell lung cancer.
    Schneider PM; Praeuer HW; Stoeltzing O; Boehm J; Manning J; Metzger R; Fink U; Wegerer S; Hoelscher AH; Roth JA
    Br J Cancer; 2000 Aug; 83(4):473-9. PubMed ID: 10945494
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Potential role of bcl-2 as a suppressor of tumour angiogenesis in non-small-cell lung cancer.
    Koukourakis MI; Giatromanolaki A; O'Byrne KJ; Whitehouse RM; Talbot DC; Gatter KC; Harris AL
    Int J Cancer; 1997 Dec; 74(6):565-70. PubMed ID: 9421349
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of automated cellular imaging system and manual microscopy for immunohistochemically stained cryostat sections of lung cancer specimens applying p53, ki-67 and p120.
    Hilbe W; Gächter A; Duba HC; Dirnhofer S; Eisterer W; Schmid T; Mildner A; Bodner J; Wöll E
    Oncol Rep; 2003; 10(1):15-20. PubMed ID: 12469137
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Use of neuroendocrine markers, p53, and HER2 to predict response to chemotherapy in patients with stage III non-small cell lung cancer: a Cancer and Leukemia Group B study.
    Graziano SL; Tatum A; Herndon JE; Box J; Memoli V; Green MR; Kern JA
    Lung Cancer; 2001; 33(2-3):115-23. PubMed ID: 11551406
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prognostic value of immunohistochemical staining of p53, bcl-2, and Ki-67 in small cell lung cancer.
    Paik KH; Park YH; Ryoo BY; Yang SH; Lee JC; Kim CH; Ki SS; Kim JM; Park MJ; Ahn HJ; Choi W; Chung JH
    J Korean Med Sci; 2006 Feb; 21(1):35-9. PubMed ID: 16479062
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Vascular endothelial growth factor, wild-type p53, and angiogenesis in early operable non-small cell lung cancer.
    Giatromanolaki A; Koukourakis MI; Kakolyris S; Turley H; O'Byrne K; Scott PA; Pezzella F; Georgoulias V; Harris AL; Gatter KC
    Clin Cancer Res; 1998 Dec; 4(12):3017-24. PubMed ID: 9865915
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A multiparametric study on the prognostic value of epidermal growth factor receptor in operable breast carcinoma.
    Gasparini G; Boracchi P; Bevilacqua P; Mezzetti M; Pozza F; Weidner N
    Breast Cancer Res Treat; 1994 Jan; 29(1):59-71. PubMed ID: 7912568
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Predictive survival markers in patients with surgically resected non-small cell lung carcinoma.
    Moldvay J; Scheid P; Wild P; Nabil K; Siat J; Borrelly J; Marie B; Farré G; Labib T; Pottier G; Sesboüé R; Bronner C; Vignaud JM; Martinet Y; Martinet N
    Clin Cancer Res; 2000 Mar; 6(3):1125-34. PubMed ID: 10741743
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Alterations of K-ras, p53, and erbB-2/neu in human lung adenocarcinomas.
    Bongiorno PF; Whyte RI; Lesser EJ; Moore JH; Orringer MB; Beer DG
    J Thorac Cardiovasc Surg; 1994 Feb; 107(2):590-5. PubMed ID: 7905543
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Determination of biological parameters on fine-needle aspirates from non-small cell lung cancer.
    Bozzetti C; Guazzi A; Nizzoli R; Naldi N; Franciosi V; Cascinu S
    Methods Mol Med; 2003; 75():405-20. PubMed ID: 12407756
    [No Abstract]   [Full Text] [Related]  

  • 34. C-erbB-2 oncoprotein expression in operable non-small cell lung cancer.
    Giatromanolaki A; Gorgoulis V; Chetty R; Koukourakis MI; Whitehouse R; Kittas C; Veslemes M; Gatter KC; Iordanoglou I
    Anticancer Res; 1996; 16(2):987-93. PubMed ID: 8687165
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prognostic implications of p53 protein, epidermal growth factor receptor, and Ki-67 labelling in brain tumours.
    Jaros E; Perry RH; Adam L; Kelly PJ; Crawford PJ; Kalbag RM; Mendelow AD; Sengupta RP; Pearson AD
    Br J Cancer; 1992 Aug; 66(2):373-85. PubMed ID: 1503912
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Oncogene proteins and proliferation antigens in thymomas: increased expression of epidermal growth factor receptor and Ki67 antigen.
    Gilhus NE; Jones M; Turley H; Gatter KC; Nagvekar N; Newsom-Davis J; Willcox N
    J Clin Pathol; 1995 May; 48(5):447-55. PubMed ID: 7629292
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Biological variables in non-small cell lung cancer: comparison between immunocytochemical determination on fine needle aspirates from surgical specimens and immunohistochemical determination on tissue sections.
    Bozzetti C; Franciosi V; Crafa P; Carbognani P; Rusca M; Nizzoli R; Guazzi A; Naldi N; Cocconi G
    Lung Cancer; 2000 Jul; 29(1):33-41. PubMed ID: 10880845
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Non-small cell lung carcinoma: cyclin D1, bcl-2, p53, Ki-67 and HER-2 proteins expression in resected tumors.
    Radović S; Babić M; Dorić M; Hukić A; Kuskunović S; Hadzismajlović A; Serdarević F
    Bosn J Basic Med Sci; 2007 Aug; 7(3):205-11. PubMed ID: 17848143
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Matrix metalloproteinase expression in human breast cancer: an immunohistochemical study including correlation with cathepsin D, type IV collagen, laminin, fibronectin, EGFR, c-erbB-2 oncoprotein, p53, steroid receptors status and proliferative indices.
    Ioachim EE; Athanassiadou SE; Kamina S; Carassavoglou K; Agnantis NJ
    Anticancer Res; 1998; 18(3A):1665-70. PubMed ID: 9673387
    [TBL] [Abstract][Full Text] [Related]  

  • 40. p53, c-erbB-2 and the epidermal growth factor receptor in the benign and malignant prostate.
    Mellon K; Thompson S; Charlton RG; Marsh C; Robinson M; Lane DP; Harris AL; Horne CH; Neal DE
    J Urol; 1992 Feb; 147(2):496-9. PubMed ID: 1370701
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.